Background: Treatment options for chronic osmotic demyelination syndrome are limited to case reports and only a very few show complete recovery. We report a case of complete recovery of chronic osmotic demyelination syndrome with plasmapheresis.
Case Presentation: A 43-year-old Sri Lankan man presented with fever, repeated vomiting, unsteady gait, increased tonicity of his right upper limb and paucity of speech for three days. He was treated in the local hospital with antibiotics and antivirals as per central nervous system infection. He had hyponatraemia, which was rapidly corrected with hypertonic saline from 97 to 119 mmol/L. He was transferred to our hospital because of progressive reduction of consciousness, rapidly worsening rigidity and bradykinesia of all four limbs and worsening dysarthria and bradyphrenia. Magnetic resonance imaging of the brain was compatible with osmotic demyelination syndrome. He was commenced on plasmapheresis twenty-two days after rapid correction of sodium. He regained independent mobility with complete resolution of rigidity, bradykinesia and speech dysfunction after five cycles of alternate day plasmapheresis.
Conclusion: Plasmapheresis can be considered as an effective treatment modality in chronic osmotic demyelination syndrome.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798224 | PMC |
http://dx.doi.org/10.1186/s13256-020-02573-9 | DOI Listing |
East Asian Arch Psychiatry
December 2024
Department of Radiology, Tuen Mun Hospital, Hong Kong SAR, China.
Endocr Pract
December 2024
Department of Endocrinology, King's College Hospital NHS Foundation Trust, London, United Kingdom. Electronic address:
Objectives: The recommended dose of tolvaptan for hyponatraemia secondary to SIADH is 15mg. We evaluated the efficacy of an initial 7.5mg dose and determined the frequency where sodium (Na+) correction exceeded safe limits, defined as an increment of ≥10 mmol/L, within the initial 8 or 24 hours of administration.
View Article and Find Full Text PDFMedicine (Baltimore)
December 2024
Department of Neurology and Department of Neuroscience, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Rationale: Osmotic demyelination syndrome (ODS) is a noninflammatory demyelinating disorder involving the pontis and other regions of the central nervous system. This article tries to enhance the understanding of ODS. Combined with clinical features, we use laboratory/imaging examination and literature review.
View Article and Find Full Text PDFJ Evid Based Med
December 2024
School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, China.
Objective: This study aims to investigate the occurrence of adverse events associated with topiramate by analyzing data from the FDA Adverse Event Reporting System. The goal is to provide a basis for the safe clinical use of topiramate.
Methods: Adverse event data from the FDA Adverse Event Reporting System, from its inception through the first quarter of 2024, were extracted.
Cureus
November 2024
Internal Medicine, Dubai Medical College for Girls, Dubai, ARE.
A pregnant woman was brought to the emergency department looking starved and neglected. She was diagnosed with sepsis and started on intravenous antibiotics. She was also disoriented and hypernatremic.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!